Randomized Trial of Levocarnitine Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity

12 Mar 20264 min read0 viewsINTERVENTIONAL Trial

GIST (Key Takeaways)

Official title: A Randomized Trial of Levocarnitine Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity in Adolescents and Young Adults Receiving Acute Lymphoblastic Leukemia Therapy Summary: This phase III trial compares the effect of adding levocarnitine to standard chemotherapy versus (vs.) standard chemotherapy alone in protecting the liver in patients with leukemia or lymphoma. Asparaginase is part of the standard of care chemotherapy for the treatment of acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), and mixed phenotype acute leukemia (MPAL).
However, in adolescent and young adults (AYA) ages 15-39 years, liver toxicity from asparaginase is common and often prevents delivery of planned chemotherapy, thereby potentially compromising outcomes. Some groups of people may also be at higher risk for liver damage due to the presence of fat in the liver even before starting chemotherapy.
Patients who are of Japanese descent, Native Hawaiian, Hispanic or Latinx may be at greater risk for liver damage from chemotherapy for this reason. Carnitine is a naturally occurring nutrient that is part of a typical diet and is also made by the body.

This is a phase III randomized trial evaluating whether adding levocarnitine to standard chemotherapy reduces asparaginase-associated hepatotoxicity in adolescents and young adults with certain lymphoid malignancies.
The intervention contrasts levocarnitine plus standard of care chemotherapy against standard chemotherapy alone, with the primary aim of protecting liver function during asparaginase-containing regimens.

Asparaginase is routinely used in treatment regimens for acute lymphoblastic leukemia, lymphoblastic lymphoma, and mixed phenotype acute leukemia.
In patients aged 15–39 years, liver toxicity from asparaginase frequently occurs and can impede delivery of planned therapy, potentially affecting outcomes.
The protocol notes that pre-existing hepatic steatosis or metabolic risk factors may heighten susceptibility to liver injury, with observed differential risk among individuals of Japanese descent, Native Hawaiian, or Hispanic/Latinx origins.

Levocarnitine is presented as a supplementation strategy to augment carnitine levels, a nutrient integral to metabolism, with deficiency linked to organ damage including hepatic injury.
Laboratory and clinical usage data have suggested a potential protective effect of levocarnitine against asparaginase-induced hepatotoxicity, informing the trial’s hypothesis.

The principal objective is to determine whether levocarnitine reduces the incidence of severe liver damage attributed to asparaginase chemotherapy.
The study focuses on patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, or mixed phenotype acute leukemia receiving asparaginase as part of their treatment.

The trial targets enrollment of approximately 440 participants and is currently in the recruiting phase.
The projected study completion date is December 30, 2028, with phase III designation and a primary emphasis on supportive care outcomes.

The available description is concise and does not provide detailed methodology regarding randomization, blinding, specific dosing of levocarnitine, or explicit endpoints beyond hepatotoxicity risk reduction.
No trial results, safety data, or numerical outcomes are provided in the source content.
The summary explicitly states the focus on pediatric-adult crossover (AYA) populations and acknowledges potential demographic risk modifiers, but lacks granular data on subgroup analyses or predefined statistical thresholds.